A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
Mato, A.R., Schuster, S.J., Lamanna, N., Pagel, J.M., Flinn, I.W., Barrientos, J., Reeves, J.A., Cheson, B.D., Barr, P.M., Kambhampati, S., Lansigan, F., Pu, J.J., Skarbnik, A., Fonseca, G., Dorsey, C., LaRatta, N.M., Weissbrot, H., Svoboda, J., Luning Prak, E.T., Tsao, P., Sitlinger, A., Paskalis, D., Sportelli, P., Miskin, H.P., Weiss, M.S., Brander, D.M.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article